Systemic Therapy for Hepatocellular Carcinoma.

Area of Science:

• Hepatobiliary cancers
• Medical oncology
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) systemic therapy has advanced significantly.
• Initial treatments like sorafenib have been surpassed by newer options.
• Current standards include immune checkpoint inhibitors (ICIs).

Purpose of the Study:

• To review the evolution of systemic therapy for hepatocellular carcinoma.
• To highlight current treatment standards and emerging therapeutic strategies.
• To discuss future directions in HCC treatment research.

Main Methods:

• Literature review of systemic therapies for hepatocellular carcinoma.
• Analysis of current clinical trial data and treatment guidelines.
• Identification of ongoing and future research areas.

Main Results:

• First-line therapy has shifted to ICI combinations (atezolizumab/bevacizumab, durvalumab/tremelimumab).
• Upcoming therapies include camrelizumab/rivoceranib and nivolumab/ipilimumab.
• Second-line options remain multikinase inhibitors or ramucirumab.

Conclusions:

• Immune checkpoint blockade is the new standard for first-line HCC treatment.
• Research is expanding to adjuvant settings and patients with Child-Pugh B liver function.
• Novel checkpoint molecules and combination strategies are under investigation.